Concepedia

A. Hannah

AH

Statistics

Publications

6

Citations

131

H-Index

6

Active since

2003

Affiliations

Sarah Cannon(Current)

A. Hannah is an author at Sarah Cannon specializing in pharmacology, medicine, and pharmacodynamics of anticancer agents.

Publications per year

2003–2018

6

Publications

6

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline <i>BRCA</i> mutation

Jennifer K. Litton, HS Rugo, Johannes Ettl et al. · Cancer Research · 2018 · 50 citations

, , +15

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

Alison Stopeck, SL Moulder, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2007 · 21 citations

, , +15

547 KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients (Pts) with advanced malignancies

David R. Spriggs, Jakob Dupont, S. Pezzulli et al. · European Journal of Cancer Supplements · 2003 · 19 citations

, , +14

Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)

Kathryn Miller, Lee S. Rosen, Shanu Modi et al. · Journal of Clinical Oncology · 2007 · 17 citations

, , +14

Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors

John L. Marshall, Sundar Ramalingam, Jimmy J. Hwang et al. · Journal of Clinical Oncology · 2005 · 13 citations

, , +17

1–5 of 6